ArticleEuropean journal of preventive cardiology2021
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
Article in European journal of preventive cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography in Patients With Premature Coronary Artery Disease: a Randomized Controlled Trial
Implementation of a Decision Support System and Its Effect on Early Optimisation of Lipid-Lowering Therapies in Patients With Acute Coronary Syndrome: a Cluster Randomised Controlled Trial
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of Intensive Lipid-Lowering Therapy on Coronary Plaque Stabilization Derived from Optical Coherence Tomography: a Meta-analysis and Meta-regression.Cardiovascular drugs and therapy · 2025 · on this mapPooled it
- Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat.Frontiers in cardiovascular medicine · 2022Pooled it
- Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.European heart journal open · 2026Article
- Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial.European heart journal. Digital health · 2026Article
- Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States.JACC. Advances · 2026Article
- Evaluation and AI-powered prediction of the efficacy of alirocumab use among patients with cardiovascular disease.Frontiers in pharmacology · 2026Article
- Low-frequency and rare genetic variants associated with rheumatoid arthritis risk.Nature reviews. Rheumatology · 2024Review
- Lipid Lowering Drugs in Acute Coronary Syndromes (ACS).Current atherosclerosis reports · 2023Review
- In-hospital initiation of PCSK9 inhibitors in ACS: pros and cons.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Article
- Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer.iScience · 2023Article
- Achievement of Low-Density Lipoprotein Cholesterol Targets in Cardiac Rehabilitation: Impact of the 2019 ESC/EAS Dyslipidaemia Guidelines.Journal of clinical medicine · 2022Article
- Contemporary National Patterns of Eligibility and Use of Novel Lipid-Lowering Therapies in the United States.Journal of the American Heart Association · 2022Article
- Near-infrared spectroscopy to predict plaque progression in plaque-free artery regions.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022Article
- Is it Time for Single-Pill Combinations in Dyslipidemia?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Review
- Lipid-lowering therapy and percutaneous coronary interventions.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021Review
- Lipid Lowering Drugs: Present Status and Future Developments.Current atherosclerosis reports · 2021Review
- Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?Journal of clinical medicine · 2021Review
- Safety and Tolerability of PCSK9 Inhibitors: Current Insights.Clinical pharmacology : advances and applications · 2020Review
- Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study.Therapeutic advances in cardiovascular diseaseObservational
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe 2018 American College of Cardiology (ACC)/American Heart Association (AHA) and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) lipid guidelines recently updated their recommendations regarding proprotein convertase subtilisin/kexin-9 inhibitors (PCSK9i). We assessed the potential eligibility for PCSK9i according to the new guidelines in patients with acute coronary syndromes. METHODS AND
resultsWe analysed a contemporary, prospective Swiss cohort of patients hospitalised for acute coronary syndromes. We modelled a statin intensification effect and an incremental ezetimibe effect on low-density lipoprotein-cholesterol levels among patients who were not on high-intensity statins or ezetimibe. One year after the index acute coronary syndrome event, treatment eligibility for PCSK9i was defined as low-density lipoprotein-cholesterol of 1.4 mmol/l or greater according to ESC/EAS guidelines. For ACC/AHA guidelines, treatment eligibility was defined as low-density lipoprotein-cholesterol of 1.8 mmol/l or greater in the presence of very high-risk atherosclerotic cardiovascular disease, defined by multiple major atherosclerotic cardiovascular disease events and/or high-risk conditions. Of 2521 patients, 93.2% were treated with statins (53% high-intensity statins) and 7.3% with ezetimibe at 1 year, and 54.9% had very high-risk atherosclerotic cardiovascular disease. Low-density lipoprotein-cholesterol levels less than 1.8 mmol/l and less than 1.4 mmol/l at 1 year were observed in 37.5% and 15.7% of patients, respectively. After modelling the statin intensification and ezetimibe effects, these numbers increased to 76.1% and 49%, respectively. The proportion of patients eligible for PCSK9i was 51% according to ESC/EAS criteria versus 14% according to ACC/AHA criteria.
conclusionsIn this analysis, the 2019 ESC/EAS guidelines rendered half of all post-acute coronary syndrome patients potentially eligible for PCSK9i treatment, as compared to a three-fold lower eligibility rate based on the 2018 ACC/AHA guidelines.
Indexed as
Identifiers
33755142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.